Trial Outcomes & Findings for A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation (NCT NCT06660069)
NCT ID: NCT06660069
Last Updated: 2026-03-18
Results Overview
Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
COMPLETED
NA
199 participants
Week 12
2026-03-18
Participant Flow
This study was conducted at a single center in United States of America.
A total of 199 participants were enrolled, 196 participants were randomized to treatment groups: 65 participants to the toothpaste/mouthwash group, 65 participants to the reference toothpaste group, and 66 participants to the negative control group. A total of 183 randomized participants subsequently completed the study.
Participant milestones
| Measure |
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
Participants brushed their teeth with full ribbon of test toothpaste containing Stannous Fluoride (SnF2) on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 milliliters(mL) of mouthwash containing Cetylpyridinium Chloride (CPC) vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
Reference Toothpaste (SnF2 Toothpaste)
Participants brushed their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
|---|---|---|---|
|
Overall Study
STARTED
|
65
|
65
|
66
|
|
Overall Study
COMPLETED
|
63
|
61
|
59
|
|
Overall Study
NOT COMPLETED
|
2
|
4
|
7
|
Reasons for withdrawal
| Measure |
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
Participants brushed their teeth with full ribbon of test toothpaste containing Stannous Fluoride (SnF2) on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 milliliters(mL) of mouthwash containing Cetylpyridinium Chloride (CPC) vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
Reference Toothpaste (SnF2 Toothpaste)
Participants brushed their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
2
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
2
|
7
|
Baseline Characteristics
A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
Baseline characteristics by cohort
| Measure |
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=65 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
Reference Toothpaste (SnF2 Toothpaste)
n=65 Participants
Participants brushed their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=66 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Total
n=196 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
51.8 years
STANDARD_DEVIATION 14.36 • n=110 Participants
|
47.6 years
STANDARD_DEVIATION 14.32 • n=114 Participants
|
50.7 years
STANDARD_DEVIATION 13.38 • n=224 Participants
|
50.1 years
STANDARD_DEVIATION 14.06 • n=104 Participants
|
|
Sex: Female, Male
Female
|
55 Participants
n=110 Participants
|
55 Participants
n=114 Participants
|
54 Participants
n=224 Participants
|
164 Participants
n=104 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=110 Participants
|
10 Participants
n=114 Participants
|
12 Participants
n=224 Participants
|
32 Participants
n=104 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=110 Participants
|
4 Participants
n=114 Participants
|
4 Participants
n=224 Participants
|
12 Participants
n=104 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
61 Participants
n=110 Participants
|
61 Participants
n=114 Participants
|
62 Participants
n=224 Participants
|
184 Participants
n=104 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
0 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
African American/African Heritage
|
4 Participants
n=110 Participants
|
6 Participants
n=114 Participants
|
6 Participants
n=224 Participants
|
16 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
0 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
1 Participants
n=224 Participants
|
1 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
Asian - South East Asian Heritage
|
1 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
0 Participants
n=224 Participants
|
1 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
White - Arabic/North African Heritage
|
4 Participants
n=110 Participants
|
2 Participants
n=114 Participants
|
4 Participants
n=224 Participants
|
10 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
White - White/Caucasian/European Heritage
|
55 Participants
n=110 Participants
|
57 Participants
n=114 Participants
|
54 Participants
n=224 Participants
|
166 Participants
n=104 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
1 Participants
n=110 Participants
|
0 Participants
n=114 Participants
|
1 Participants
n=224 Participants
|
2 Participants
n=104 Participants
|
PRIMARY outcome
Timeframe: Week 12Population: The modified Intention-To-Treat (mITT) population comprised of all randomized participants who received at least one dose of investigational product and completed at least one-post Baseline efficacy assessment. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=59 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)
|
24.1 bleeding sites
Standard Error 1.05
|
10.1 bleeding sites
Standard Error 1.03
|
SECONDARY outcome
Timeframe: Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=59 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
|
15.0 bleeding sites
Standard Error 0.74
|
4.5 bleeding sites
Standard Error 0.72
|
SECONDARY outcome
Timeframe: Week 6Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
|
25.0 bleeding sites
Standard Error 1.09
|
10.6 bleeding sites
Standard Error 1.09
|
SECONDARY outcome
Timeframe: Week 6Population: mITT Population.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
|
15.4 bleeding sites
Standard Error 0.76
|
5.1 bleeding sites
Standard Error 0.76
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
0.20 score on a scale
Standard Error 0.009
|
0.08 score on a scale
Standard Error 0.009
|
|
Mean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
0.19 score on a scale
Standard Error 0.009
|
0.08 score on a scale
Standard Error 0.009
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
0.18 score on a scale
Standard Error 0.009
|
0.06 score on a scale
Standard Error 0.009
|
|
Mean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
0.17 score on a scale
Standard Error 0.009
|
0.05 score on a scale
Standard Error 0.009
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
1.43 score on a scale
Standard Error 0.032
|
0.93 score on a scale
Standard Error 0.032
|
|
Mean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
1.31 score on a scale
Standard Error 0.027
|
0.78 score on a scale
Standard Error 0.027
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
1.62 score on a scale
Standard Error 0.033
|
1.13 score on a scale
Standard Error 0.033
|
|
Mean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
1.49 score on a scale
Standard Error 0.028
|
0.97 score on a scale
Standard Error 0.027
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/ palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4= Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
2.95 score on a scale
Standard Error 0.046
|
2.59 score on a scale
Standard Error 0.045
|
|
Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
2.83 score on a scale
Standard Error 0.054
|
2.38 score on a scale
Standard Error 0.052
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 6
|
3.19 score on a scale
Standard Error 0.041
|
2.88 score on a scale
Standard Error 0.040
|
|
Mean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Week 12
|
3.10 score on a scale
Standard Error 0.049
|
2.69 score on a scale
Standard Error 0.048
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Overall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
25.0 bleeding sites
Standard Error 1.09
|
14.1 bleeding sites
Standard Error 1.09
|
|
Overall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
24.1 bleeding sites
Standard Error 1.05
|
11.4 bleeding sites
Standard Error 1.04
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Interproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
15.4 bleeding sites
Standard Error 0.76
|
7.8 bleeding sites
Standard Error 0.76
|
|
Interproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
15.0 bleeding sites
Standard Error 0.74
|
6.1 bleeding sites
Standard Error 0.73
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
0.20 score on a scale
Standard Error 0.009
|
0.11 score on a scale
Standard Error 0.009
|
|
Mean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
0.19 score on a scale
Standard Error 0.009
|
0.08 score on a scale
Standard Error 0.009
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
0.18 score on a scale
Standard Error 0.009
|
0.09 score on a scale
Standard Error 0.009
|
|
Mean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
0.17 score on a scale
Standard Error 0.009
|
0.06 score on a scale
Standard Error 0.009
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
1.43 score on a scale
Standard Error 0.032
|
1.11 score on a scale
Standard Error 0.032
|
|
Mean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
1.31 score on a scale
Standard Error 0.027
|
0.88 score on a scale
Standard Error 0.027
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
1.62 score on a scale
Standard Error 0.033
|
1.31 score on a scale
Standard Error 0.032
|
|
Mean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
1.49 score on a scale
Standard Error 0.028
|
1.06 score on a scale
Standard Error 0.027
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores was recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
2.95 score on a scale
Standard Error 0.046
|
2.88 score on a scale
Standard Error 0.045
|
|
Mean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
2.83 score on a scale
Standard Error 0.054
|
2.74 score on a scale
Standard Error 0.053
|
SECONDARY outcome
Timeframe: Week 6 and Week 12Population: mITT Population. Only those participants with data available at the specified timepoint were analyzed.
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Outcome measures
| Measure |
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=62 Participants
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=63 Participants
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Mean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 6
|
3.19 score on a scale
Standard Error 0.041
|
3.15 score on a scale
Standard Error 0.040
|
|
Mean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Week 12
|
3.10 score on a scale
Standard Error 0.049
|
3.02 score on a scale
Standard Error 0.049
|
Adverse Events
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
Reference Toothpaste (SnF2 Toothpaste)
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)
n=65 participants at risk
Participants brushed their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants swished 20 mL of mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
|
Reference Toothpaste (SnF2 Toothpaste)
n=65 participants at risk
Participants brushed their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
Negative Control Toothpaste (Sodium Fluoride Toothpaste)
n=66 participants at risk
Participants brushed their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
|
|---|---|---|---|
|
Gastrointestinal disorders
Tooth Discolouration
|
21.5%
14/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Gastrointestinal disorders
Aphthous Ulcer
|
3.1%
2/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
3.1%
2/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Gastrointestinal disorders
Oral Mucosal Exfoliation
|
3.1%
2/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Gastrointestinal disorders
Tongue Coated
|
3.1%
2/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Investigations
Coronavirus Test Positive
|
0.00%
0/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
1.5%
1/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
|
Nervous system disorders
Taste Disorder
|
1.5%
1/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/65 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
0.00%
0/66 • Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study product including any washout or lead-in product (or medical device). A serious AE (SAE) was a particular category of AE where the outcome was serious.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER